Skip to content

Nitrous Oxide Vasodilation Healthy Adult Volunteers

Peripheral Vasodilation in Healthy Adult Volunteers Receiving 50% Nitrous Oxide

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01785030
Enrollment
7
Registered
2013-02-06
Start date
2013-02-28
Completion date
2017-02-28
Last updated
2019-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vein Vasodilation

Brief summary

Nitrous oxide (N2O) is a gas that is normally used to take away pain and anxiety during painful medical procedures. However, one of its effects is to also make veins appear larger and more visible. This is useful when there is a patient who needs to have an intravenous (IV) needle put in their skin to give them medicine or fluids, but may have veins that are very hard to see or feel. The mechanism of this observed effect is not entirely clear. The purpose of this study is to use an ultrasound to directly measure whether there is an actual change size of veins or change in blood flow in healthy adult volunteers when you give them 50% nitrous oxide, and see whether or not this change in size, or change in flow, is what causes the changes in visibility or palpability of the vein.

Interventions

DRUG50% Nitrous oxide

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Healthy adult volunteers. * 19 years or older (inclusive) * English speaking.

Exclusion criteria

* ASA class III or greater; * History of, or suspected, difficult airway based on physical exam, facial dysmorphism or syndrome * Any condition in which air may be trapped in a body cavity. These include, but are not limited to: Pneumothorax or chest injury, concurrent acute asthma exacerbation, middle ear occlusion, intestinal obstruction, ileus, or abdominal distension, sinusitis or maxillofacial injuries with potential for trapped gas, recent intraocular surgery or penetrating globe injury, air embolus, severe bullous emphysema (consider in patients with cystic fibrosis), history of craniotomy in previous three weeks * Pregnancy (1st and 2nd trimester) * Increased intracranial pressure, impaired level of consciousness, or head injury * Known Vitamin B12 deficiency * Known MTHFR Deficiency (Inborn error of metabolism) * History of bleomycin administration (note that the oxygen component of N2O administration is what interacts with bleomycin to cause pulmonary toxicity) * Intoxication with alcohol or other drugs * Any condition in which patient may be catecholamine-depleted (e.g. septic shock) * Recent history of altered mental status * Pulmonary hypertension * Congestive heart failure. * Trainees, including students, residents, and fellows, working in the pediatric emergency department.

Design outcomes

Primary

MeasureTime frame
Diameter of peripheral vein (mm)15-30 minutes at time of enrolment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026